rethinkTHC Search
Menu
Study breakdown

THC produced the same physiological effects in HIV-model rats and healthy controls without worsening HIV-related motivation deficits

Animal StudyPreliminary evidence
The takeaway

In HIV transgenic rats, THC produced consistent dose-dependent effects on pain sensitivity, body temperature, and locomotion regardless of HIV status, and chronic THC treatment did not worsen HIV-related motivation deficits.

HIV/AIDS researchers, cannabis pharmacologists, people living with HIV who use cannabis

Chronic THC (16 days) did not worsen HIV-related motivation deficits in rats

What the researchers found

THC at 3 mg/kg reduced pain sensitivity, body temperature, and locomotor activity across all genotypes, with some sex-dependent effects. HIV transgenic rats showed lower motivation than one control strain but not the other, and while acute THC reduced motivation, chronic treatment (16 days) did not.

Why it matters

People living with HIV use cannabis at higher rates than the general population, often to manage symptoms. Understanding whether THC worsens or improves HIV-associated motivational deficits is important for clinical guidance.

The numbers in context

46 HIV-1tg rats; 87 control rats (WT and F344); THC doses: 0, 0.3, 3 mg/kg; 16 days chronic treatment; 3 mg/kg THC reduced breakpoints acutely but not after chronic dosing

How the study worked

Two experiments using female and male HIV-1 transgenic rats and two control strains (wildtype littermates and Fischer344). Experiment 1 tested acute THC effects using the cannabinoid tetrad assay (nociception, temperature, locomotion). Experiment 2 used the Progressive Ratio Breakpoint Task to assess motivation at baseline, after acute THC, and after 16 days of chronic THC.

What this study cannot tell us

Animal model may not fully replicate human HIV or cannabis use patterns. HIV transgenic rats only showed motivation deficits compared to one control strain, raising questions about the model itself. THC was administered by injection rather than smoked or vaped.

How to read the evidence

Preliminary: animal study with relatively small sample sizes and questions about control strain selection. Findings need human confirmation.

When this study was published

2026 publication using the HIV-1 transgenic rat model.

The bigger picture

This study suggests THC does not exacerbate HIV-related motivation problems, at least in this animal model. Combined with reports that cannabis helps manage HIV-related symptoms like nausea and appetite loss, it paints a more nuanced picture of cannabis use in this population.

Questions still open

  • Would longer chronic THC exposure eventually affect motivation? Do results translate to humans living with HIV? Does the choice of control strain significantly influence conclusions about HIV-related behavioral deficits?

Common questions

Does THC affect HIV-positive and HIV-negative rats differently?
No. THC produced the same physiological effects (reduced pain sensitivity, lower body temperature, less movement) regardless of HIV status, with some sex-based differences.
Did chronic THC use reduce motivation?
Only acutely. A single dose of 3 mg/kg THC reduced motivation, but after 16 days of daily treatment, this effect disappeared, suggesting tolerance developed.

Read the original research

THC induced similar physiological effects on HIV transgenic rats and their controls without affecting HIV-induced deficits in effortful motivation.

Journal of cannabis research, 8(1), 17

Citation

Vemuri, Sunitha; Ayoub, Samantha M; Minassian, Arpi; Young, Jared W. (2026). THC induced similar physiological effects on HIV transgenic rats and their controls without affecting HIV-induced deficits in effortful motivation.. Journal of cannabis research, 8(1), 17. https://doi.org/10.1186/s42238-025-00383-8

Explore the wider topic